MGX
Metagenomi Inc. Common Stock
السعر في الوقت الحقيقي
مخطط الأسعار
المقاييس الرئيسية
مقاييس السوق
الافتتاح
$1.475
الأعلى
$1.475
الأدنى
$1.475
الحجم
0.25M
أساسيات الشركة
إحصاءات التداول
أخبار ذات صلة
Chardan Capital Maintains Buy on Metagenomi, Lowers Price Target to $12
Chardan Capital analyst Geulah Livshits maintains Metagenomi with a Buy and lowers the price target from $13 to $12.
Wells Fargo Maintains Overweight on Metagenomi, Lowers Price Target to $16
Wells Fargo analyst Yanan Zhu maintains Metagenomi with a Overweight and lowers the price target from $20 to $16.
Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025
- Potential best-in-class extrahepatic in vivo gene editing with all-in-one delivery to the central nervous system (CNS) is a critical milestone for the treatment of neurological disorders - - Advancements demonstrate
Metagenomi to Present at Upcoming Scientific Meetings
EMERYVILLE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (NASDAQ:MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing
أسهم ذات صلة
ابق على اطلاع
تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.